Sunday, June 28, 2020 8:38:09 AM
$AIM Stock Price History
Beta (5Y Monthly) -0.91
52-Week Change 3 -38.69%
S&P500 52-Week Change 3 1.51%
52 Week High 3 7.1100
52 Week Low 3 0.3800
50-Day Moving Average 3 2.5215
200-Day Moving Average 3 1.8087
Beta (5Y Monthly) -0.91
52-Week Change 3 -38.69%
S&P500 52-Week Change 3 1.51%
52 Week High 3 7.1100
52 Week Low 3 0.3800
50-Day Moving Average 3 2.5215
200-Day Moving Average 3 1.8087
Recent AIM News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/27/2026 09:30:45 PM
- AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors • GlobeNewswire Inc. • 03/18/2026 12:36:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/16/2026 09:30:12 PM
- AIM ImmunoTech Announces Closing of its Rights Offering • GlobeNewswire Inc. • 03/07/2026 12:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 10:15:32 PM
- AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million • GlobeNewswire Inc. • 03/04/2026 02:00:00 PM
- AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer • GlobeNewswire Inc. • 03/02/2026 02:00:00 PM
- AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering • GlobeNewswire Inc. • 02/27/2026 02:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/27/2026 01:30:11 PM
- AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026 • GlobeNewswire Inc. • 02/25/2026 02:00:00 PM
- AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 02/23/2026 01:55:00 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/17/2026 01:15:30 PM
- AIM ImmunoTech Announces Commencement of Rights Offering • GlobeNewswire Inc. • 02/12/2026 09:35:00 PM
- AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event • GlobeNewswire Inc. • 02/12/2026 01:55:00 PM
- AIM ImmunoTech Announces Commencement of Rights Offering • GlobeNewswire Inc. • 02/11/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/11/2026 05:15:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2026 10:03:20 PM
- AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/06/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 01:40:53 PM
- AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer • GlobeNewswire Inc. • 02/05/2026 01:40:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/29/2026 09:31:00 PM
- AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering • GlobeNewswire Inc. • 01/27/2026 09:35:00 PM
- AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering • GlobeNewswire Inc. • 01/23/2026 06:22:21 PM
